Commentary

Video

DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma

Author(s):

Grzegorz S. Nowakowski, MD,Samuel Yamshon, MD

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

Related Videos
Lori A Leslie, MD
Andrew Ip, MD
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Dasom (Caroline) Lee, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Shaji Kumar, MD
Related Content
Yousef Zakharia, MD, medical oncologist, vice chair, Genitourinary Malignancy Disease Group, Mayo Clinic Comprehensive Cancer Center; medical director, Experimental Therapeutics Clinic, Mayo Clinic
January 15th 2025

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Roxana S. Dronca, MD
January 13th 2025

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Naseema Gangat, MBBS, of Mayo Clinic
January 10th 2025

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

Dasom (Caroline) Lee, MD
January 6th 2025

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL